蛋白名稱:FCGR3A人重組蛋白,10389-H08H
蛋白構(gòu)建:A DNA sequence encoding the extracellular domain (Met 1-Gln 208) of human CD16a (P08637-1) precursor was expressed with a C-terminal polyhistidine tag.
表達宿主:HEK293 Cells
蛋白純度:≥ 95 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC. ≥ 90 % as determined by SEC-MALS(Routinely tested).
蛋白活性:
1.Loaded Human FcγRIIIA / CD16a (F176) recombinant protein (Cat. 10389-H08H ) on His1K Biosensor, can bind Bevacizumab (IgG1) with an affinity constant of 1.9 μM as determined in a BLI assay (Sartorius Octet Red384) (Routinely tested).
2.Captured Bevacizumab (IgG1) on proA Chip can bind Human FcγRIIIA / CD16a (F176) recombinant protein (Cat. 10389-H08H ) with an affinity constant of 2.67 µM as determined in an SPR assay (Biacore T200) (Routinely tested).
3.Recombinant Human CD16a/FCGR3A/Fc gamma RIIIA Protein (176F), His Tag (Cat. No. 10389-H08H) captured on CM5 Chip via Anti-his antibody chip, can bind Rituximab derived Anti-CD20 antibody, Human IgG1 with an affinity constant of 0.499 µM as determined in an SPR assay (Biacore T200) (QC tested).
蛋白內(nèi)毒素:< 1.0 EU per μg of the protein as determined by the LAL method
預測N端:Gly 17
蛋白分子量:The secreted recombinant human CD16a consists of 203 amino acids and has a predicted molecular mass of 23.3 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of human CD16a is approximately 45.2 kDa due to glycosylation. The molecular weight of this protein is around 36-48 kDa verified by SEC-MALS (Routinely tested).
蛋白NP號:P08637-1
蛋白氨基酸序列:Met1-Gln208,176F
蛋白標簽:C-His
歡迎去義翹神州網(wǎng)查看FCGR3A人重組蛋白,10389-H08H詳細信息。
義翹神州研發(fā)團隊擁有多年的重組蛋白研發(fā)經(jīng)驗。多年來,我們的團隊已開發(fā)出超過9300余種重組蛋白,涵蓋免疫檢查點、抗體藥物靶點、CAR-T細胞治療靶點、Fc受體、流感病毒蛋白以及細胞因子等熱門研究領域。義翹神州重組蛋白具有高純度、高生物活性和低內(nèi)毒素水平等特性,可為生物藥靶點發(fā)現(xiàn)、蛋白質(zhì)結(jié)構(gòu)和功能分析、細胞療法和重組酶酶學性質(zhì)等科學研究提供支持。
義翹神州利用蛋白表達平臺,提供重組蛋白生產(chǎn)"一站式"技術服務。我們的服務包括蛋白基因合成、蛋白質(zhì)密碼子優(yōu)化、蛋白質(zhì)表達載體設計、大規(guī)模細胞培養(yǎng)和發(fā)酵、蛋白純化和蛋白質(zhì)量控制檢測。我們在蛋白表達和大規(guī)模生產(chǎn)方面有著顯著的成本節(jié)約和速度優(yōu)勢,同時在設計各種類型的重組蛋白純化項目(帶或不帶純化標簽)方面也擁有著豐富的經(jīng)驗和專業(yè)技術。 義翹神州擁有經(jīng)驗豐富的技術團隊,每年可研發(fā)生產(chǎn)1,000+種重組蛋白開發(fā)和大規(guī)模生產(chǎn)項目。我們有能力進行快速的蛋白質(zhì)表達和純化工藝開發(fā),根據(jù)需求進行工藝放大研究,并且可滿足高通量和大規(guī)模批量生產(chǎn)蛋白質(zhì)的要求。 我們致力于成為重組蛋白和單克隆抗體大規(guī)模生產(chǎn)的實驗室,為藥物研發(fā)企業(yè)和生命科學機構(gòu)提供高水平的技術服務。
歡迎小伙伴來咨詢哦! 請注明來源、姓名,單位!